In part 3 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the remaining challenges in the work with of translating stem cell-derived beta cells to the clinic.
Jon Odorico MD is Director of the Pancreas and Islet Cell Transplantation Programs and Professor in the Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health.
Transcript of this video segment:
Challenges of Translating Stem Cell-Derived Beta Cells to the Clinic
Odorico: There are a number of challenges still. They include improving functionality yet to a more mature population. We still are missing an understanding of some of the key signals at the last phase of development that are probably important for robust-functionally developed islet-like clusters and beta cells. In addition, we need to better understand the immunogenicity of the cells, both in the autologous cells and for allogeneic cells, and, in the autoimmune setting as well as in the allogenic setting.
Finally, we really need to improve the transplant site; the liver is not an ideal site and many groups are working on sites including the omentum, subcutaneous, prevascularized sites, intramuscular sites – sites that are potentially retrievable. That’s important when thinking about stem cells and the possibility of rogue cells.